Business Context and Reporting Period
This Form 6-K filing by Clearmind Medicine Inc. covers the month of April 2026. The report details a material amendment to a Convertible Loan Agreement (CLA) and significant changes to the composition of the Board of Directors.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin data for the period. The primary financial disclosure relates to the Company's debt capacity:
- Convertible Promissory Notes: The Company has an aggregate principal capacity of up to $10,000,000 under the SPAs entered into on September 17, 2025.
- Available Capacity: As of April 30, 2026, the full $10,000,000 subscription amount remains available for future issuances.
Material Changes
CLA Amendment
On April 30, 2026, the Company and CLA Investors amended the Securities Purchase Agreements (SPAs). The amendment confirmed that the full $10,000,000 capacity remains available for future issuances of Promissory Notes.
Board of Director Updates
- Resignation: Mr. Amitay Weiss, Chairman of the Board, resigned effective April 26, 2026. The resignation was not due to any disagreement with the Company or its management.
- Appointments: On April 27, 2026, Ms. Hila Kiron-Revach was appointed Chairperson of the Board. Mr. Asaf Itzhaik was appointed to the Compensation Committee and the Nominating and Corporate Governance Committee.
- Committee Composition:
- Audit Committee: Chaired by Mr. Asaf Itzhaik; members include Ms. Hila Kiron-Revach and Mr. Yehonatan Shachar.
- Compensation Committee: Chaired by Mr. Oz Adler; members include Mr. Asaf Itzhaik and Mr. Yehonatan Shachar.
- Nominating and Corporate Governance Committee: Chaired by Mr. Yehonatan Shachar; members include Mr. Oz Adler and Mr. Asaf Itzhaik.
- Independence: The Board determined that Ms. Hila Kiron-Revach, Mr. Yehonatan Shachar, and Mr. Asaf Itzhaik are independent directors under Nasdaq listing rules.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, outlook, or management commentary regarding future operational performance. The primary risk factor disclosed is the potential dilution or debt obligation associated with the future issuance of up to $10,000,000 in convertible promissory notes.
Investor Verification Checklist
- Verify the terms of the Amendment to the Securities Purchase Agreement (Exhibit 10.1) to understand conversion rates and interest terms.
- Confirm the timeline for the appointment of a new CEO or interim leadership if Mr. Weiss's resignation impacts executive operations.
- Monitor future filings for the actual drawdown of the $10,000,000 convertible note facility.
- Review the Company's most recent Form 20-F for detailed financial statements, as this 6-K does not include them.